Intravascular ultrasound restenosis trial progresses
This article was originally published in Clinica
Executive Summary
PharmaSonics has completed the enrolment phase of its pivotal SWING and Euro-SPAH trials for assessing its intravascular ultrasound therapy for reducing restenosis. The release of the trial results are expected to coincide with pivotal trial data from another new technology for addressing restenosis - drug-coated stents.